[Form 3] Hemab Therapeutics Holdings, Inc. Initial Statement of Beneficial Ownership
Hemab Therapeutics Holdings, Inc. insiders associated with RA Capital filed an initial ownership report showing indirect holdings of Series A, B and C Preferred Stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Hemab Therapeutics Holdings, Inc. insiders associated with RA Capital filed an initial ownership report showing indirect holdings of Series A, B and C Preferred Stock. These preferred shares are each convertible into Common Stock on a 22-for-1 basis immediately prior to the closing of the company’s initial public offering for no additional consideration.
The filing lists indirect positions held by RA Capital Healthcare Fund LP and RA Capital Nexus Funds II and IV, including Series A Preferred Stock convertible into 609,840 and 1,422,960 underlying Common Stock shares, Series B Preferred Stock convertible into 399,212 and 931,502 underlying shares, and Series C Preferred Stock convertible into 221,188 and 1,253,384 underlying shares. RA Capital Management and related parties disclaim beneficial ownership except to the extent of their pecuniary interest.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Series A Preferred Stock | -- | -- | -- |
| holding | Series A Preferred Stock | -- | -- | -- |
| holding | Series B Preferred Stock | -- | -- | -- |
| holding | Series B Preferred Stock | -- | -- | -- |
| holding | Series C Preferred Stock | -- | -- | -- |
| holding | Series C Preferred Stock | -- | -- | -- |
Footnotes (5)
- F1. Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock will automatically convert into shares of Common Stock on a 22-for-1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and has no expiration date.
- F2. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II") and RA Capital Nexus IV Fund, L.P. (the "Nexus Fund IV"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund II, the Nexus Fund IV, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
- F3. Held directly by the Fund.
- F4. Held directly by Nexus Fund II.
- F5. Held directly by Nexus Fund IV.
AI-generated analysis. How Rhea-AI works. Not financial advice.
